Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DAVIAD

Financiado

Cerrado

The development of a novel therapeutic vaccine for the selective treatment of th...

The development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder Graves disease This aim of the DAVIAD proposal is to develop a therapeutic vaccine for Graves’ disease (GD) that has a better safety and efficacy profile than current treatments. There is a high level of unmet need in the treatment of Graves’ di... ver más

30/06/2018

VOEDSELBANK LIMBUR...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

VOEDSELBANK LIMBURG No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-06-30 No tenemos la información de la convocatoria

0% 71% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

VOEDSELBANK LIMBURG

0.00€ | Lider

GSKBIO

N.D. | Participante

QPAR

885.61K€ | Participante

Proyectos interesantes

RYC2021-033828-I

Medical Technol...

Biomedical Imag...

236K€ Cerrado

DIAPREPP

Medical Technol...

Health Informat...

8M€ Cerrado

SAF2009-10622

Medical Technol...

Immunology

353K€ Cerrado

BIO2014-53091-C3-1-R

Medical Technol...

Nanotechnology

157K€ Cerrado

GAPAID

Medical Technol...

Biomedical Imag...

2M€ Cerrado

PTQ2023-013188

Medical Technol...

Biomedical Imag...

78K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

VOEDSELBANK LIMBURG No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This aim of the DAVIAD proposal is to develop a therapeutic vaccine for Graves’ disease (GD) that has a better safety and efficacy profile than current treatments. There is a high level of unmet need in the treatment of Graves’ disease especially in patients with Graves orbitopathy and children and adolescents (who generally suffer from the most chronic form of the disease). Autoimmune diseases arise as a consequence of a hypersensitive response to self antigens. This proposal focuses on the development of an antigen specific vaccine therapy to reinstate immune tolerance to Graves’ disease. The selected peptides behave as apitopes (antigen processing independent epitopes) and bind to MHC class II molecules in the correct confirmation to induce tolerance. In the first instance DAVIAD will further characterise antigen specific peptides (based on the autoantigen associated with the disease) already selected using a validated discovery platform. DAVIAD will generate translational data to support a clinical trial application, conduct disease model studies and prepare the clinical trial application. DAVIAD will design and conduct a phase I/IIa trial in GD patients to show that efficacy and safety compare favourably with current treatments and those in development. The consortium has the expertise required to effectively and efficiently take the proposed vaccine through clinical development and eventual commercialisation. A disease modifying vaccine for GD will address a serious unmet need and potentially offer a therapy that can change the way this disease is treated, offering better quality of life for sufferers and reducing burden on health services.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores